New York, NYNCT07288398Now EnrollingIRB Ready

Pulmonary Hypertension Associated With HFpEF Clinical Trial in New York, NY

Access cutting-edge pulmonary hypertension associated with hfpef treatment through this clinical trial at a research site in New York. Study-provided care at no cost to qualified participants.

Sponsored by Tenax Therapeutics, Inc.

Quick Self-Assessment

See if you qualify for this New York location

Preparing your pre-screening questions…

Expert Care in New York

Access pulmonary hypertension associated with hfpef specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related pulmonary hypertension associated with hfpef treatment provided free

Apply for This New York Location

Check if you qualify for this pulmonary hypertension associated with hfpef clinical trial in New York, NY

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to New York

    Convenient for NY residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit New York site if eligible
  4. 4Begin participation

About This Pulmonary Hypertension Associated With HFpEF Study in New York

The purpose of this study is to assess the efficacy and safety of the study drug, levosimendan (given orally), compared to placebo in participants with pulmonary hypertension with heart failure with preserved left ventricular ejection fraction (PH-HFpEF) as measured by the change in 6-Minute Walk Distance.

Sponsor: Tenax Therapeutics, Inc.

Who Can Participate

Inclusion Criteria

Men or women, ≥18 to 85 years of age
NYHA Class II or III or ambulatory NYHA Class IV symptoms
A diagnosis of World Health Organization (WHO) Group 2 PH-HFpEF with qualifying hemodynamics verified by right heart catheterization (RHC)
A qualifying baseline RHC
A qualifying echocardiogram
A qualifying 6-MWD
A 48-hour ambulatory cardiac rhythm monitor during the Screening Period
Requirements related to child bearing potential, contraception, and egg/sperm donation)

Exclusion Criteria

A diagnosis of PH WHO Groups 1, 3, 4, or 5
Echocardiographic evidence for hypertrophic cardiomyopathy, restrictive cardiomyopathy, constrictive pericarditis, cardiac amyloidosis, or infiltrative cardiomyopathy
Structural heart repair or replacement of the aortic valve or mitral valve (surgical or percutaneous) OR, planned valve intervention OR, the presence of significant valve disease
A diagnosis of pre-existing lung disease
History of severe allergic or anaphylactic reaction or hypersensitivity to the excipients in the investigational product
Major surgery within 60 days
Prior heart, lung, or heart-lung transplants or life expectancy of \<12 months
History of clinically significant other diseases that may limit or complicate participation in the study

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in New York?

Yes, this clinical trial (NCT07288398) has an active research site in New York, NY that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Pulmonary Hypertension Associated With HFpEF Treatment Options in New York, NY

If you're searching for pulmonary hypertension associated with hfpef treatment options in New York, NY, this clinical trial (NCT07288398) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our New York research site is actively enrolling participants for this clinical trial. You'll receive care from experienced pulmonary hypertension associated with hfpef specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all pulmonary hypertension associated with hfpef clinical trials near you to find additional studies recruiting in your area.

More Heart Failure Trials in New York, NY

See all heart failure clinical trials recruiting in New York — not just this study.

Browse Heart Failure Trials in New York →

Browse More Trials by Condition

Heart Failure TrialsHypertension TrialsPulmonary Embolism TrialsAnkylosing Spondylitis TrialsPulmonary Hypertension TrialsErectile Dysfunction TrialsAll Conditions →

Ready to Join in New York?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · New York, NY